NanOlogy enrolls first patient in phase 12 clinical trial of NanoDoce to treat bladder cancer

NanOlogy enrolls first patient in phase 1/2 clinical trial of NanoDoce to treat bladder cancer

04:02 EDT 10 Apr 2019 | Pharmaceutical Business Review

The Phase 1/2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoDoce for patients with high-risk non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer

More From BioPortfolio on "NanOlogy enrolls first patient in phase 1/2 clinical trial of NanoDoce to treat bladder cancer"